Press Releases

ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates

ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
ADCT-402 (loncastuximab tesirine) continues to demonstrate acceptable safety profile and anti-tumor activity in patients with relapsed or refractory diffuse large B-cell lymphoma; data from 183-patient study supports continued evaluation in ongoing pivotal Phase II trial ADCT-301 (camidanlumab tesirine) achieves 86.5 percent overall response rate in heavily pretreated patients with Hodgkin lymphoma; data from 113-patient study

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Trial of CD22-targeting antibody drug conjugate being led by The University of Texas MD Anderson Cancer Center Lausanne, Switzerland, November 27, 2018 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patients have been dosed in a Phase

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting

ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
New clinical data highlight potential of novel pyrrolobenzodiazepine-based antibody drug conjugates for the treatment of relapsed or refractory lymphomas Lausanne, Switzerland, November 14, 2018 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that data from Phase I clinical trials of

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Potential new immune-oncology therapy uses antibody drug conjugate (ADC) that targets regulatory T cells (Tregs) Highly potent anti-tumor activity of CD25-targeted ADC demonstrated in preclinical solid tumor models both as monotherapy and in combination with a PD-1 inhibitor Company plans to initiate Phase Ib clinical trial to evaluate safety, tolerability and preliminary anti-tumor activity of

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase II trial evaluating efficacy and safety of CD19-targeting antibody drug conjugate intended to support submission of Biologics License Application Top-line data expected in third quarter of 2019 Lausanne, Switzerland, August 7, 2018 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today

ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors

ADC Therapeutics Announces the Termination of its ADCT-502 Program Targeting HER2 Expressing Solid Tumors
Data on safety, tolerability, pharmacokinetics and efficacy did not demonstrate sufficient patient benefit to justify further development Lausanne, Switzerland, April 25th, 2018 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has terminated the Phase

ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting

ADC Therapeutics to Present Two New Investigational Antibody-Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
Lausanne, Switzerland, April 11, 2018 – ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced its presence at the Annual Meeting of the American Association for Cancer Research (AACR) taking place April 14-18, 2018 in Chicago, USA. Two